Financing Needs
Continuous funding required for growth and development
- Materiality
- high
Ascelia Pharma
Ascelia Pharma is a Swedish pharmaceutical company headquartered in Malmö, with a US base in New Jersey. The company focuses on developing and commercializing novel drugs for rare cancer conditions, addressing unmet medical needs. Ascelia Pharma's key products include Orviglance, a contrast agent for liver imaging, and Oncoral, an oral chemotherapy drug. The company is listed on NASDAQ Stockholm under the ticker ACE and aims to become a leader in orphan oncology through strategic partnerships and an expanding product pipeline.
4.35
4.29
| % | |
|---|---|
| Contrast Agents | 50% Includes Orviglance for liver imaging |
| Chemotherapy Drugs | 30% Includes Oncoral, an oral chemotherapy drug |
| Pipeline Development | 20% Research and development of new drugs |
Ascelia Pharma primarily targets healthcare providers and hospitals that require specialized drugs for rare cancer...
- Healthcare Providersprimary
Purchase specialized cancer drugs for patient treatment
- Hospitalsprimary
Use contrast agents for imaging procedures
- Commercial Partnerssecondary
Collaborate for drug distribution and commercialization
Ascelia Pharma is headquartered in Malmö, Sweden, with a significant presence in the US through its base in New Jersey...
- •Headquartered in Malmö, Sweden
- •US base in New Jersey
- •US market accounts for 45% of Orviglance sales
- •Europe and Japan are key markets
- •Global marketing strategy through partnerships
Ascelia Pharma's strategic priorities include advancing its product pipeline and expanding its market presence through...
01
Product Launchshort-term
To establish market presence and generate revenue
02
Pipeline Expansionmedium-term
To address unmet medical needs and diversify offerings
03
Commercial Partnershipsshort-term
To leverage established market capabilities
Ascelia Pharma faces several risks, including the need for continuous financing to support its development and growth...
Regulatory Hurdles
Compliance with pharmaceutical regulations
- Materiality
- high
Partnership Dependency
Reliance on partners for commercialization
- Materiality
- medium
Fair Value Measurements
high
Share-Based Remuneration
medium
BioInvent International
BINV.ST · Health Care
BioInvent International is a biotechnology company focused on developing novel immuno-modulatory antibodies for cancer therapy.
GENELUX Corp
GNLX · Pharmaceutical Preparations
GENELUX Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing oncolytic vaccinia virus immunotherapies, led by its Olvi-Vec program.
ALX ONCOLOGY HOLDINGS INC
ALXO · Pharmaceutical Preparations
ALX Oncology Holdings Inc is a clinical-stage biotechnology company developing immuno-oncology therapies for cancer, headquartered in South San Francisco, California.
Cantargia
CANTA.ST · Health Care
Cantargia is a Swedish biotechnology company focused on developing targeted antibody-based drugs for cancer, immunological, and other life-threatening diseases.
Nuvectis Pharma, Inc.
NVCT · Pharmaceutical Preparations
ALNYLAM PHARMACEUTICALS, INC.
ALNY · Pharmaceutical Preparations
: 11/08/2026